MORPHOLOGICAL MECHANISMS OF ORGANELLE FUNCTION AND TRANSFORMATION IN CULTURE CELL

恶性肿瘤发生后，细胞的性质发生了许多变化， 转型我们最近集中研究了表达方式的变化 可能代表肿瘤特异性标志物的表面分子， 用于诊断和治疗人类肿瘤。使用 杂交瘤技术和形态学方法，我们继续分离 针对人肿瘤细胞上的表面表位的单克隆抗体。通过 用MCF-7培养的人乳腺癌细胞免疫小鼠，我们 产生了一系列相关的单克隆抗体（B1、B2、B3、K2、K3）， 乳腺、结肠、胃腺癌中表达的粘蛋白样物质 和其他器官。这些抗体正在进行诊断和 治疗用途。使用OVCAR-3人类卵巢癌细胞，我们 产生了一种新的抗体，K1，它识别一个独特的表位， 与卵巢癌中发现的CA 125抗原相似的抗原。这个新 抗体可能被证明对诊断筛选有用，也许对治疗有用 卵巢癌我们还评估了一种抗体， Neu癌基因产物的结构域，其可用于治疗 乳腺、卵巢或其他器官的选定肿瘤。在其他研究中，我们有 开始检测化疗药物的细胞内分布 柔红霉素的一种新的电子显微镜方法，我们也有 在表达人EGF受体的小鼠中定位转基因产物， 在精母细胞分化的特定阶段仅存在于睾丸中。

There are many changes in the properties of cells following malignant transformation. We have recently concentrated on changes in the expression of surface molecules that might represent tumor-specific markers that could be exploited both for diagnosis and therapy of human tumors. Using hybridoma technology and morphologic methods, we have continued to isolate monoclonal antibodies to surface epitopes on human tumor cells. By immunizing mice with MCF-7 cultured human breast tumor cells, we have generated a series of related monoclonal antibodies (B1, B2, B3, K2, K3) to mucin-like materials expressed in adenocarcinomas of breast, colon, stomach and other organs. These antibodies are under evaluation for diagnostic and therapeutic use. Using OVCAR-3 human ovarian cancer cells, we have generated a new antibody, K1, that recognizes a unique epitope on an antigen similar to the CA125 antigen found in ovarian cancer. This new antibody may prove useful for diagnostic screening and perhaps for therapy of ovarian cancer. We have also evaluated an antibody to the external domain of the Neu oncogen product, which may be useful for therapy in selected tumors of breast, ovary or other organs. In other studies, we have begun examining the intracellular distribution of the chemotherapeutic drug daunomycin by a novel electron microscopic approach, and we have also localized a transgene product in mice expressing the human EGF receptor exclusively in testis at specific stages of spermatocyte differentiation.